focus -WSS

focus

author：hotspot 2025-10-01 22:59:08 - browse：6

John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT — John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： In the gardens at Boston Children's Hospital, families find sanctuary

WSS

STAT Report: Patient voices and perspectives

Alabama hospital puts IVF treatments on hold

STAT readers on older presidents, polypills, Medicare, and more

NIH study of ME/CFS points to clear biological hallmarks

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

6 phony surgeries that take placebo to the extreme

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Antivenom research: Lessons from HIV applied in search for universal antidote

23andMe had bad news about my health. I wish a person had delivered it

With competition flaring, obesity drug hits goal in liver disease study

Activists slam private health insurers over coverage restrictions

Roche’s Alnylam deal shows drug firms interested in heart drugs

DIEP, the 'gold standard' of breast reconstruction, is under threat

CDC Director Mandy Cohen on transparency, trust, and health

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Obesity drugs seen as possible treatment for liver disease MASH

explore

In utero gene editing: an explainer

What to watch for from Zogenix and Amicus clinical trials

Alabama IVF ruling threatens families facing fatal genetic disease

Device maker Teleflex to acquire urology company for $600M

The haunting brain science of long Covid

Biden warns of ‘dark winter’ during final presidental debate

knowledge

explore

knowledge

knowledge